This move is archived. Current quotes and coverage live on the stock page.
Get MBX alerts:
Microbix Biosystems Inc. is making headlines with a remarkable 5.17% surge in its stock price today.
Microbix Biosystems Inc. (MBX.TO) has caught the attention of Canadian investors with a notable increase of 5.17% in its stock price, closing at CA$0.30. This rise is especially significant considering the company's recent performance and market conditions.
Advertisement
Microbix Biosystems Inc.
MBX.TO
MBX.TO
Microbix Biosystems Inc.
WealthAwesomeMarket cap
$40.41M
52W high
$0.33
52W low
$0.21
1W change
-4.92%
Beta
0.57
Analyst Price Targets
Based on analyst covering MBX
Wall Street analysts forecast MBX stock price to rise 37.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.40
+37.9% Upside
Current Price
C$0.29
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBX's historical volatility
30-Day Vol
51.0%
Annualized
90-Day Vol
51.5%
Annualized
Trend (90d)
+30.0%
Annualized drift
90d Mean
C$0.32
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.30 | C$0.25 โ C$0.36 |
| 60 trading days | C$0.31 | C$0.24 โ C$0.40 |
| 90 trading days | C$0.32 | C$0.24 โ C$0.44 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should think about Microbix's recent financial results and its improvements in manufacturing capabilities, which could indicate a positive path for the company.
5.17% Surge in Stock Price
Microbix's stock price climbed to CA$0.30, showing investor optimism amid recent operational advancements.
Bull case
Microbix reported a 13% revenue increase for Q1 2026, along with improvements in its manufacturing capabilities. This positions the company for potential growth in the diagnostics sector.
Bear case
Despite today's gains, Microbix still faces challenges, such as a negative profit margin and the need for steady revenue growth to maintain investor confidence.
Recent Performance Overview
Advertisement
Microbix Biosystems Inc. has seen a significant boost in its stock price, closing at CA$0.30 after a 5.17% increase. This performance follows their recent Q1 2026 financial results, which showed a 13% revenue growth compared to the previous quarter.
Strategic Advancements
The company has made progress in enhancing its test-ingredient manufacturing capabilities, which could give it a competitive edge in the diagnostics sector. These advancements may play a key role in attracting investor interest and driving future growth.
Looking Ahead
As Microbix prepares to release its Q2 2026 financial statements, investors will be closely watching for continued improvements in revenue and operational efficiency. The upcoming webinar discussion scheduled for May 14, 2026, may also provide insights into the company's strategic direction.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
